Showing results (421-430 of 976) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|April 16, 2024
Clinicopathological characteristics and eligibility for adjuvant olaparib of germline BRCA1/2 mutation carriers with HER2-negative early breast cancerStefania Morganti, Qingchun Jin, Julie Vincuilla, et al.
NPJ Breast Cancer|April 25, 2024
Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancerSara A Hurvitz, Aditya Bardia, Kevin Punie, et al.
NPJ Breast Cancer|February 10, 2026
Validation of the HER2DX genomic test in first-line advanced HER2-positive breast cancer treated with trastuzumab, pertuzumab, and taxaneMarcin Kubeczko, Sandra Cobo, Rodrigo Sanchez-Bayona, et al.
NPJ Breast Cancer|January 27, 2026
Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trialToralf Reimer, Angrit Stachs, Kristina Veselinovic, et al.
NPJ Breast Cancer|February 13, 2026
Programmable local immunochemotherapy for triple-negative breast cancer via spatiotemporally controlled release of CpG oligodeoxynucleotides, gemcitabine, and paclitaxelCheng-Hsien Hsieh, Ming-Yi Hsu, Chiou-Feng Lin, et al.
NPJ Breast Cancer|January 30, 2026
The CXCL10/CXCR3 axis is essential for sustaining immunological dormancy in triple-negative breast cancerAlev Yilmaz, Lisa Haerri, Mateo Estrella Granda, et al.
NPJ Breast Cancer|December 13, 2025
Illuminating the clinicopathological and genomic landscape of HER2-null, ultralow, and low breast cancers: insights into diagnostic discordance between biopsy and surgical excisionMing Li, Meng-Yuan Cai, Hong Lv, et al.
NPJ Breast Cancer|November 29, 2025
Plasma assay of methylated DNA markers detects recurrent metastatic breast cancerKarthik V Giridhar, Jason P Sinnwell, Seth W Slettedahl, et al.
NPJ Breast Cancer|November 24, 2025
Nomogram for predicting axillary pathologic complete response in cN2-3 breast cancer after neoadjuvant chemotherapyJeong Hun Oh, Soyeon Ahn, Mijung Jang, et al.
NPJ Breast Cancer|November 18, 2025
Field cancerization, accelerated aging, and immunosuppression: the rapid rise of hormone-sensitive and early-onset breast cancerMeadow Parrish, Nicole Traugh, Meloryn Seraj, et al.
Pageof 98